Clinical Trial Update: Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update reports pharmacokinetics and safety data for meropenem in infants under 90 days with meningitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis

Drugs mentioned

• Merrem (meropenem)

Snippet

Sponsor: PENTA Foundation | Conditions: Meningitis | Phase 1, Phase 2 | Status: COMPLETED